GET DAILY SIGNALSEvolus (EOLS) Posts +13% Revenue Growth in Q3 2026 While Building Toward Profitability
Key Takeaways
- Evolus reported third-quarter 2026 global net revenue of $78 million, a 13% increase year over year and modestly above the consensus estimate of about $77.6 million.
- GAAP earnings came in at a loss of $0.19 per share, wider than the consensus estimate of roughly a $0.07 loss per share.
- Adjusted EBITDA was positive for a fourth consecutive quarter, improving by $4 million versus the prior year.
- Management reaffirmed its full-year 2026 outlook and its 2028 long-term targets, including $450 million to $500 million in total net revenue.
- The company expects U.S. Food and Drug Administration (FDA) approval of Evolysse Sculpt by the end of 2026, a key portfolio catalyst.
- For more details on Evolus, explore Major News, Today's Price Move, Price Targets, and Forecast.
- Discover new market opportunities with Trending AI Robots.
Why This Quarter Matters
Evolus is a global performance beauty company best known for Jeuveau, its injectable neurotoxin dedicated exclusively to aesthetics, alongside a growing portfolio of hyaluronic acid (HA) fillers and skin-quality products. This quarterly report matters because it tests whether Evolus can sustain double-digit revenue growth while steadily converting that growth into profitability. The third quarter was particularly important as the company continued commercializing its Evolysse and Estyme HA gel lines and awaited FDA action on Evolysse Sculpt. With adjusted EBITDA now positive for four straight quarters, I am watching whether operating leverage is durable enough to support the company's ambitious multi-year targets.
Reported Results
Evolus delivered third-quarter 2026 global net revenue of $78 million, up 13% from the prior-year period and slightly ahead of the consensus estimate of approximately $77.6 million. Global toxin revenue reached $70.1 million, while injectable HA products contributed $7.9 million. Through the first nine months of 2026, total net revenue rose 14% year over year to $235.2 million.
On the bottom line, Evolus posted a GAAP net loss of $0.19 per share, wider than the consensus expectation of roughly a $0.07 loss per share. Reported gross margin was 65%, while adjusted gross margin, which excludes amortization of intangible assets, was 66.1%. Management highlighted a fourth consecutive quarter of positive adjusted EBITDA, with a $4 million year-over-year improvement, reflecting ongoing operating leverage. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Evolus shares closed at $7.47 on the day of the report, with the stock ticking modestly higher in after-hours trading as investors weighed the revenue beat against the wider-than-expected GAAP loss. Sentiment around the name remains focused on two themes: the durability of double-digit revenue growth and the pace at which Evolus converts that growth into positive earnings. The fourth consecutive quarter of positive adjusted EBITDA was viewed constructively, reinforcing confidence in the company's expense discipline, even as the headline EPS miss reminded investors that GAAP profitability is still a work in progress.
Forward Outlook and Key Factors to Monitor
Evolus reaffirmed its full-year 2026 financial outlook, including an expectation that its Evolysse and Estyme injectable HA gels will contribute 10% to 12% of full-year total net revenue. The company also maintained its low- to mid-single-digit adjusted EBITDA margin target for 2026 and its 2028 long-term outlook of $450 million to $500 million in total net revenue, implying a three-year compound annual growth rate (CAGR) of 15% to 19%.
The most closely watched near-term catalyst is the anticipated FDA approval of Evolysse Sculpt by the end of 2026. Approval would expand the company's filler portfolio and, management has indicated, support progress toward its 2028 objectives. Investors should also monitor the timeline for an Evolysse lips submission, planned before year-end, with a potential launch in early 2028.
Beyond injectables, Evolus continues to develop a longer-term pipeline that includes Profhilo for skin quality, with U.S. approval anticipated around 2030, and an option to acquire a hair-growth asset. Gross margin trends, HA gel adoption, and the pace of operating expense growth will remain important signals of whether the company can sustain its path toward broader profitability without sacrificing commercial momentum. From what I see, these milestones will be worth tracking closely.
Integrating AI Into My Research Process
When analyzing earnings reports like this one from Evolus, I find it helpful to cross-reference data with AI-driven tools for additional context on patterns and peer comparisons. Tickeron’s AI Screener allows me to quickly filter stocks based on technical signals, fundamentals, and performance metrics, which helps refine ideas without replacing traditional analysis. It has become a regular part of how I prepare for these quarterly updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EOLS in -4.79% downward trend, falling for three consecutive days on November 02, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EOLS declined for three days, in 240 of 301 cases, the price declined further within the following month. The odds of a continued downward trend are 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 55 cases where EOLS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
EOLS moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EOLS crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for EOLS entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EOLS's RSI Oscillator exited the oversold zone, 27 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on EOLS as a result. In 60 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for EOLS just turned positive on October 28, 2026. Looking at past instances where EOLS's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.
Following a +4.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where EOLS advanced for three days, in 208 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
EOLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-15.966) is normal, around the industry mean (7.659). P/E Ratio (-14.094) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.646) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. EOLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EOLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of neurotoxins
Industry PharmaceuticalsGeneric
Advertisement